Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk

Feb. 29, 2012 - PRLog -- GBI Research finds that the global diabetes therapeutics market is lucrative despite the declining sales of Actos and Avandia. The major factor driving the growth of the market is the rising prevalence rate of the diabetic population in key markets such as the US, the UK and Germany.

The global diabetes prevalence population in 2010 was estimated at 61.5 million, in which Type 1 diabetes was estimated at 7.2 million and Type 2 diabetes was estimated at 54.3 million. The Type 2 diabetes market accounted for 72% of the global diabetes therapeutics market. The diabetes market has also witnessed some product failures. Avandia (rosiglitazone), belonging to the class of thiazolidinedones, was found to increase the probability of heart risks. Following the discovery of the side effects, the sales of Avandia plunged alarmingly. The Avandia products recorded peak sales of $3 billion in 2006, falling to $572m in 2010. In addition, Actos (pioglitazone hydrochloride), another thiazolidinedone, acquired market share from Avandia, although it was also found to be associated with increasing risk of heart related complications. Nevertheless, the diabetes market still remained attractive due to increased utilization of other drugs such as insulin analogues and biguanides. At the same time, some of the promising molecules in the peptide analogues class are expected to be launched in the market.

GBI Research forecasts that the diabetes therapeutics market will grow at 7.1% between 2010 and 2017. The market will be primarily driven by the rising prevalence rates and the market entry of new products such as Teplizumab, Syncria, Alogliptin, Bydureon, Dapagliflozin, Canagliflozin, and some new molecules belonging to the peptide analogues class.

For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Diabete...


GBI Research finds the global diabetes therapeutics market to be a concentrated market, with the top three companies (Novo Nordisk, Sanofi and Takeda) accounting for close to 60% of the total global market share in the diabetes portfolio. These three companies are the leading players in the diabetes market. The competitive landscape in the markets is set to change due to the success of recent launches of antidiabetic drugs. The market will also be impacted by the decline in sales of leading products such as GSK’s Avandia and Takeda’s Actos.

GBI Research, the leading business intelligence provider, has released its latest research “Diabetes Therapeutics Market to 2017- Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global diabetes therapeutics market. The report analyzes the markets for diabetes in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and prices are forecast up to 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Diabetes-Therapeuti...


Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com            
North America:                   +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.